Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 2/20 | 0.50 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.41 |
| ▸ | TYR | P14679 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GABRP | O00591 | 1/20 | 0.39 |
| ▸ | GABRD | O14764 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10339809 | 0.90 | NOS2 (0.46) | NOS2SKP2TLR8TYRNOS3 | |
| SCHEMBL20788166 | 0.86 | NOS2 (0.47) | NOS2SKP2NOS3NOS1ALDH1A1 | |
| Methane SCHEMBL16027128 | 0.82 | TLR8 (0.41) | NOS2SKP2TLR8TYRALDH1A1 | |
| SCHEMBL6131314 | 0.82 | SKP2 (0.47) | NOS2SKP2TLR8TYRHTT | |
| SCHEMBL13890665 | 0.81 | NOS2 (0.46) | NOS2SKP2TLR8TYRNOS3 | |
| SCHEMBL831156 | 0.80 | SKP2 (0.41) | NOS2SKP2TLR8TYRHTT | |
| SCHEMBL27876554 | 0.80 | SKP2 (0.41) | NOS2SKP2TLR8TYRHTT | |
| SCHEMBL11691828 | 0.79 | NOS2 (0.42) | NOS2SKP2TLR8TYRALDH1A1 | |
| SCHEMBL5385969 | 0.78 | TLR8 (0.39) | NOS2SKP2TLR8TYRALDH1A1 | |
| SCHEMBL3939086 | 0.78 | TLR8 (0.39) | NOS2SKP2TLR8TYRGABRP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10815317-B2 | Method for producing oligomer and catalyst | ENEOS CORPORATION (JP) | 2020-10-27 | — | — | US | disclosed |
| US-20190077888-A1 | METHOD FOR PRODUCING OLIGOMER AND CATALYST | JXTG NIPPON OIL & ENERGY CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| CN-108602909-A | The manufacturing method and catalyst of oligomer | JXTG能源株式会社 | 2018-09-28 | — | — | CN | disclosed |
| US-20160108310-A1 | WAVELENGTH CONVERSION FILMS WITH MULTIPLE PHOTOSTABLE ORGANIC CHROMOPHORES | NITTO DENKO CORPORATION (JP) | 2016-04-21 | — | — | US | disclosed |
| US-20150340519-A1 | HIGHLY-FLUORESCENT AND PHOTO-STABLE CHROMOPHORES FOR WAVELENGTH CONVERSION | NITTO DENKO CORPORATION (JP) | 2015-11-26 | — | — | US | disclosed |
| US-6821644-B2 | BIS(DIARYLAMINO)ARYLENE COMPOUND; BRILLIANCE, DURABILITY | SAMSUNG SDI CO., LTD. (KR) | 2004-11-23 | — | — | US | disclosed |
| US-20010012571-A1 | Organic electroluminescent device | SAMSUNG DISPLAY CO., LTD. (KR) | 2001-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10815317-B2 | Method for producing oligomer and catalyst | AOC2, ZRANB2, PICALM | NOS2 1070/4885SKP2 782/4885TLR8 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.